分享:
分享到微信朋友圈
X
技术研究
T1-mapping与RESOLVE DWI在中轴型脊柱关节炎骶髂关节炎症活动性定量评估中的比较研究
张潇 杨晟升 陈贤源 方坤华 俞顺

Cite this article as: ZHANG X, YANG S S, CHEN X Y, et al. Comparative study of T1-mapping and RESOLVE DWI in the quantitative assessment of sacroiliac joint inflammatory activity in axial spondyloarthritis[J]. Chin J Magn Reson Imaging, 2026, 17(4): 101-108.本文引用格式:张潇, 杨晟升, 陈贤源, 等. T1-mapping与RESOLVE DWI在中轴型脊柱关节炎骶髂关节炎症活动性定量评估中的比较研究[J]. 磁共振成像, 2026, 17(4): 101-108. DOI:10.12015/issn.1674-8034.2026.04.014.


[摘要] 目的 比较T1-mapping与分段读出平面回波弥散加权成像(readout segmentation of long variable echo-train diffusion-weighted imaging, RESOLVE DWI)技术在定量评估中轴型脊柱关节炎(axial spondyloarthropathy, axSpA)骶髂关节炎症活动性水平的诊断效能,旨在为临床提供更具价值的定量指标。材料与方法 回顾性收集2017年6月至2024年6月于福州大学附属省立医院风湿科确诊的74例axSpA患者为病例组,19例因机械性下腰痛接受骶髂关节MRI检查者为对照组。病例组中依据强直性脊柱炎疾病活动度评分(Ankylosing Spondylitis Disease Activity Score, ASDAS)分为活动组(n=40)与非活动组(n=34)。所有研究对象均行骶髂关节常规MRI检查及T1-mapping与RESOLVE DWI定量技术检查,同步测量两组骶髂关节软骨下骨髓的T1-mapping值、表观扩散系数(apparent diffusion coefficient, ADC)(b=50、500、700 s/mm2,记为ADC50, 500, 700)。比较对照组、病例组及其亚组(非活动组和活动组)间T1-mapping值与ADC50, 500, 700值的差异,采用受试者工作特征(receiver operating characteristic, ROC)曲线分析T1-mapping、ADC50, 500, 700在不同组间的诊断效能,并计算曲线下面积(area under the curve, AUC)。DeLong检验用于比较二组间AUC值的差异。结果 病例组、非活动组、活动组骶髂关节关节软骨下骨髓的T1-mapping值与ADC50, 500, 700值均高于对照组(均P<0.001)。活动组骶髂关节关节软骨下骨髓的T1-mapping值与ADC50, 500, 700值高于非活动组(P<0.05)。在区分对照组与病例组中,T1-mapping与ADC50, 500, 700的AUC分别为0.889和0.877;在区分对照组与非活动组中,AUC分别为0.811和0.828;在区分对照组与活动组中,AUC分别为0.955和0.918,均显示出良好的诊断效能,经DeLong检验差异无统计学意义(P均>0.05);在区分非活动组与活动组时,T1-mapping的AUC为0.808,而ADC50, 500, 700的AUC为0.693,差异具有统计学意义(P=0.042)。结论 T1-mapping与RESOLVE DWI技术均能够较好地评估axSpA骶髂关节炎症活动性水平,且在区分axSpA患者非活动组与活动组评估中,T1-mapping技术效能更优。
[Abstract] Objective This study compares the diagnostic efficacy of T1-mapping and readout segmentation of long variable echo-train diffusion-weighted imaging (RESOLVE DWI) techniques in quantitatively assessing sacroiliac joint inflammation activity levels in axial spondyloarthropathy (axSpA), aiming to provide clinicians with more valuable quantitative indicators.Materials and Methods The retrospective cohort study included 74 patients diagnosed with axial spondyloarthropathy (axSpA) at the Department of Rheumatology, Provincial Hospital Affiliated to Fuzhou University between June 2017 and June 2024, forming the case group. A control group comprised 19 individuals who underwent sacroiliac joint MRI examinations for mechanical low back pain. Within the case group, participants were further categorised into an active group (n = 40) and an inactive group (n = 34) based on the Ankylosing Spondylitis Disease Activity Score (ASDAS). All research subjects underwent conventional MRI, T1-mapping, and RESOLVE DWI quantitative technical inspection. T1-mapping values and apparent diffusion coefficient (b = 50, 500, 700 s/mm2, denoted as ADC50, 500, 700) of the subchondral bone marrow in the sacroiliac joints were measured simultaneously across both groups. Comparisons were made between the control group, case group, and its subgroups (inactive and active groups) regarding differences in T1-mapping values and ADC50, 500, 700 values. The diagnostic efficacy of T1-mapping and ADC50, 500, 700 across groups was analysed using receiver operating characteristic (ROC) curves, and the area under the curve (AUC) was calculated. The DeLong test was used to compare the differences in AUC values between the two groups.Results The T1-mapping values and ADC50, 500, 700 values of the subchondral bone marrow in the sacroiliac joint were higher in the case group, inactive group, and active group than in the control group (P < 0.001 for all comparisons). The T1-mapping values and ADC50, 500, 700 values of the subchondral bone marrow in the sacroiliac joint of the active group were higher than those in the inactive group (P < 0.05). In distinguishing the control group from the case group, the AUC values for T1-mapping and ADC50, 500, 700 were 0.889 and 0.877 respectively; when differentiating the control group from the inactive group, the AUC values were 0.811 and 0.828 respectively. In distinguishing the control group from the active group, the AUC values were 0.955 and 0.918 respectively, both demonstrating good diagnostic performance. The Delong test indicated no statistically significant difference between them (all P > 0.05). When distinguishing between inactive and active groups, the AUC for T1-mapping was 0.808, whereas the AUC for ADC50, 500, 700 was 0.693, with a statistically significant difference (P = 0.042).Conclusions Both T1-mapping and RESOLVE DWI techniques effectively assess the level of sacroiliac joint inflammation activity in axial spondyloarthritis (axSpA). However, T1-mapping demonstrates superior efficacy in distinguishing between inactive and active groups among axSpA patients.
[关键词] 中轴型脊柱关节炎;磁共振成像;T1-mapping;弥散加权成像;骨髓水肿;定量评估
[Keywords] axial spondyloarthritis;magnetic resonance imaging;T1-mapping;diffusion-weighted imaging;bone marrow edema;quantitative assessment

张潇 1, 2   杨晟升 2   陈贤源 2, 3   方坤华 2, 4   俞顺 1, 2, 5*  

1 福建中医药大学中西医结合学院中西医结合研究院,福州 350122

2 福建医科大学省立临床医学院,福建省立医院放射科,福州大学附属省立医院放射科,福州 350001

3 福州市第二医院妇幼保健院放射科,福州 350008

4 福建省龙岩市第二医院放射科,龙岩 364000

5 福建省医疗大数据工程重点实验室,福州 350001

通信作者:俞顺,E-mail: 76429310@qq.com

作者贡献声明::俞顺负责本研究整体的构思与方案设计,并对稿件重要内容进行了修改,获得福建省财政厅科技计划项目、福建省卫生健康科技计划项目的资助。张潇负责研究数据的获取、分析与解释,并完成了稿件的起草与撰写;杨晟升、陈贤源、方坤华参与了本研究数据的获取、分析或解释工作,并对稿件的重要内容进行了修改。全体作者均已审阅并同意论文的最后修改稿,承诺对本研究的所有方面负责,确保研究的准确性与学术诚信。


基金项目: 福建省财政厅科技计划项目 2023248 福建省卫生健康科技计划项目 2024XA007
收稿日期:2025-12-03
接受日期:2026-03-23
中图分类号:R445.2  R684.3 
文献标识码:A
DOI: 10.12015/issn.1674-8034.2026.04.014
本文引用格式:张潇, 杨晟升, 陈贤源, 等. T1-mapping与RESOLVE DWI在中轴型脊柱关节炎骶髂关节炎症活动性定量评估中的比较研究[J]. 磁共振成像, 2026, 17(4): 101-108. DOI:10.12015/issn.1674-8034.2026.04.014.

0 引言

       中轴型脊柱关节炎(axial spondyloarthritis, axSpA)往往最早累及骶髂关节[1, 2],临床表现为中轴骨及外周关节疼痛、僵直[3],同时常伴有关节外症状如炎症性肠病、急性前葡萄膜炎和银屑病等病变[4, 5]。axSpA好发于青壮年,男女比例约为2∶1,全球发病率约为0.5%[6, 7],其慢性炎症和致残性严重损害患者的日常功能与生活质量[8]。axSpA疾病活动性水平呈周期性改变,非活动期和活动期交替,而高疾病活动水平与患者预后相关[9, 10]。目前,临床上对于axSpA炎症活动性评估多以患者的主观描述、医师的体格检查及综合评分等工具为基础[11]。强直性脊柱炎疾病活动度评分(Ankylosing Spondylitis Disease Activity Score, ASDAS)[12, 13]作为评估疾病活动和制订治疗决策的首选工具,临床应用广泛。然而,虽然ASDAS包含了一定的客观指标,如C反应蛋白(C-reactive protein, CRP)和红细胞沉降率(erythrocyte sedimentation rate, ESR),但公式中仍有超过一半的权重来自患者的自我评估。因此,患者的心理状态与合并症可能是影响评分结果的混杂因素。同时,其反映的是整体疾病活动状态,难以直接表征骶髂关节局部炎症负荷。相比之下,定量参数可从局部组织层面提供更客观的炎症信息。MRI因其软组织分辨率高和无辐射的优点,成为检出axSpA患者骶髂关节炎特征性的骨髓水肿(bone marrow edema, BME)的首选成像技术[14, 15]。但常规MRI受三大瓶颈制约:其一,肉眼上观察低级别水肿敏感性低,早期病变易被漏诊;其二,图像判读高度依赖医师经验,主观性强,观察者间差异显著;其三,无法对炎症程度进行精确定量,因而难以动态监测治疗反应,限制了实时指导治疗与疗效评估的临床价值。

       随着影像学技术的发展,各种功能成像逐渐应用于临床。T1-mapping通过定量测量组织的弛豫时间来分析器官组织的微观特征,反映相应的生理功能和结构状态[16]。研究表明,利用T1-mapping可以检测骨髓内含水量的细微改变,从而定量评估骨关节病变[17, 18]。分段读出平面回波弥散加权成像(readout segmentation of long variable echo-train diffusion-weighted imaging, RESOLVE DWI)是一种高分辨率、低畸变的先进扩散加权成像技术,能有效评估组织中水分子的扩散情况,并通过表观扩散系数(apparent diffusion coefficient, ADC)进行量化,更加准确地显示病灶[19]。既往研究多提示T1-mapping和RESOLVE DWI技术均可用于评估axSpA骶髂关节炎症活动性,但多为分别评价其诊断效能,缺乏以ASDAS作为临床参考标准对两种技术进行直接比较的研究[20, 21, 22]。因此,基于ASDAS这一临床参考标准比较不同MRI定量技术在炎症活动性评估中的诊断效能,有助于明确其相对优势,并为临床影像技术选择提供依据。故本研究以ASDAS作为参考标准,对比T1-mapping与RESOLVE DWI技术定量在评估axSpA患者骶髂关节炎性活动性的诊断效能,旨在探索出一个更优的更适用于临床的检测手段,有望为骶髂关节炎症活动性评估提供客观量化依据,辅助早期诊断与治疗决策。

1 材料与方法

1.1 研究对象

       回顾性收集2017年6月至2024年6月于福州大学附属省立医院风湿科确诊的74例axSpA患者为病例组,19例因机械性下腰痛接受骶髂关节MRI检查者作为对照组。本研究遵守《赫尔辛基宣言》及相关伦理规范,经福州大学附属省立医院伦理委员会审批同意,免除受试者知情同意(批准文号:伦审科研第K2024-06-024号)。

       病例组纳入标准:(1)符合2009年国际脊柱关节炎评价工作组(Assessment of Spondyloarthritis International Society, ASAS)发布的axSpA诊断标准[23];(2)骶髂关节常规MRI及T1-mapping、RESOLVE DWI序列影像资料完整;(3)临床资料(ASDAS评分、CRP)完整。对照组纳入标准:(1)因机械性下腰痛性行骶髂关节MRI检查,常规MRI及T1-mapping、RESOLVE DWI序列影像资料完整,且双侧骶髂关节软骨下骨髓在脂肪抑制质子密度加权成像(proton density weighted imaging with fat suppression, PDWI-FS)上无高信号;(2)临床资料完整。病例组与对照组排除标准:(1)严重的运动伪影或磁敏感伪影,影响图像观察;(2)除axSpA外有其他自身免疫性疾病史;(3)骶髂关节有肿瘤、创伤、感染或其他病变;(4)近6个月使用非甾体类药物或激素、免疫药物史。

1.2 研究对象分组

       收集研究对象的临床资料,包括:患者性别、确诊年龄。同时收集每个研究对象的ASDAS-CRP评分。根据ASDAS-CRP评分,axSpA患者分为非活动组(ASDAS<1.30)与活动组(ASDAS≥1.30)。对照组ASDAS=0。

1.3 图像采集

       所有受试者均在1.5 T磁共振扫描仪(Magnetom Aera,西门子医疗系统有限公司,埃尔朗根,德国)上完成骶髂关节MRI扫描,采用18通道腹部相控阵线圈。检查方位采用仰卧位、头先进模式,体表定位中心位于两侧髂前上棘连线与腹部正中线的交点。入组患者均进行常规MRI序列、T1-mapping序列、RESOLVE DWI序列扫描,具体扫描参数见表1

表1  磁共振扫描序列参数
Tab. 1  Magnetic resonance imaging sequence parameters

1.4 图像分析

       T1-mapping和RESOLVE DWI原始图由人工采用syngo MRD13后处理工作站(西门子医疗系统有限公司,埃尔朗根,德国)进行处理,并生成T1-mapping伪彩图及ADC图像。两名经过培训的放射科医师(阅片者1和阅片者2,分别有3年和5年骨肌影像工作经验的住院医师和主治医师)分别在T1-mapping伪彩图和ADC图上手工勾画感兴趣区(region of interest, ROI),两位阅片者分别选取炎症最重的层面,如果意见存在分歧,则由阅片者3(有20年骨肌影像工作经验的主任医师)进行裁定。所有阅片者均未知患者的临床资料及分组情况,并独立完成测量。

       根据常规MRI序列,将骶髂关节软骨下骨髓分为4个区域(左髂侧、左骶侧、右髂侧和右骶侧),每个区域分别放置3个ROI。为了指导ROI的放置,本研究参照斜冠状位PDWI-FS序列,将观察到的骶髂关节软骨面下的BME作为活动性炎症的标志。总体测量原则如下:如果骶髂关节的软骨下骨髓中未观察到BME,则将3个ROI(25~35 mm2)分别放置于软骨下骨髓的上、中、下三个区域(图1B和1C);如果在骶髂关节的软骨下骨髓中观察到BME,则将三个不重叠的圆形ROI(25~35 mm2)分别放置在T1-mapping伪彩图和ADC图中最高信号强度对应的区域上,ROI大小根据病变的大小进行调整(图1E和1F)。在放置ROI时,应避免骨皮质、骨髓脂肪变、骨质硬化区、血管和囊变区域。最终,每位患者骶髂关节的T1-mapping伪彩图和ADC图分别获取12个ROI(骶侧6个ROI和髂侧6个ROI)。每位患者分别计算髂侧和骶侧ROI测量值的平均值,并选择两者(骶侧和髂侧)间最大值作为该患者骶髂关节的T1-mapping值与ADC值。为减少测量误差,将两位阅片者采集的骶髂关节T1 -mapping值与ADC值的取平均值作为最终的结果。

图1  T1-mapping 伪彩图和ADC 图ROI 绘制示意图。1A、1B 和1C 分别为无骨髓水肿患者的PDWI-FS、ADC图和T1-mapping 伪彩图。1D、1E 和1F 分别为存在骨髓水肿患者的PDWI-FS、ADC 图和T1-mapping 伪彩图。若未见BME(1A、1B和1C),在软骨下骨髓上、中、下区域放置3 个ROI。若见到BME(1D、1E 和1F),则在T1-mapping 伪彩图和ADC 图中BME信号最强区域放置ROI。图中圆圈表示ROI。ADC:表观弥散系数;ROI:感兴趣区域;PDWI-FS:脂肪抑制质子密度加权成像;BME:骨髓水肿。
Fig. 1  Schematic diagram of ROI drawing for T1-mapping pseudo-color images and ADC maps. 1A, 1B, and 1C represent the PDWI-FS, ADC maps, and T1-mapping pseudo-color, respectively, for a patient without BME. 1D, 1E, and 1F represent the PDWI-FS, ADC maps, and T1-mapping pseudo-color, respectively, for a patient with bone marrow oedema. Where BME is absent (1A, 1B and 1C), three ROIs are placed in the upper, middle and lower regions of the subchondral bone marrow. Where BME is present (1D, 1E and 1F), the ROI is placed in the region of strongest BME signal on the T1-mapping pseudo-color image and ADC map. Circles in the figure denote the ROIs. ADC: apparent diffusion coefficient; ROI: region of interest; PDWI-FS: proton density weighted imaging with fat suppression; BME: bone marrow edema.

1.5 统计学分析

       所有数据均使用SPSS 25.0和MedCalc 15.6软件进行统计学分析。对于计量资料采用Shapiro-Wilk进行正态性检验和Levene方差齐性检验,符合正态分布的计量资料采用均数±标准差表示,方差齐的两组间比较使用独立样本t检验,若方差不齐使用t´检验;非正态分布的计量资料采用中位数(上下四分位数)表示,两组间比较用Mann-Whitney U秩和检验。对于计数资料,采用频数(频率)表示,两组间对比使用卡方检验和Fisher确切概率法。两名阅片者的测量结果采用组内相关系数(intra-class correlation coefficient, ICC)进行一致性检验,以评价阅片者间一致性,若一致性良好,后续分析采用两位阅片者测量值的平均值进行统计分析。采用受试者工作特征(receiver operating characteristic, ROC)曲线评估T1-mapping值、ADC值在对照组与axSpA组、非活动组与活动组间的诊断效能,计算曲线下面积(area under the curve, AUC)和95%置信区间(confidence interval, CI),使用约登指数获得最佳诊断阈值,并计算敏感性及特异性。采用DeLong检验比较T1-mapping值、ADC值之间AUC值差异。P<0.05表示差异具有统计学意义。

2 结果

2.1 一般资料

       对照组与病例组、对照组与非活动组、对照组与活动组以及非活动组与活动组间年龄和性别差异均无统计学意义(均P>0.05)(表2)。

表2  各组基线资料比较
Tab. 2  Comparison of baseline data across groups

2.2 阅片者间一致性分析

       两名阅片者对T1-mapping值(ICC=0.954,95% CI:0.931~0.969)和ADC50, 500, 700值(ICC=0.903,95% CI:0.857~0.934)测量结果的一致性良好。

2.3 对照组、病例组及其亚组间关节软骨下骨髓T1-mapping值对比

       病例组的T1-mapping值高于对照组,组间差异具有统计学意义(P<0.001)。亚组分析显示,非活动组与活动组的T1-mapping值均高于对照组,组间差异具有统计学意义(P<0.001);活动组的T1-mapping值高于非活动组,差异具有统计学意义(P<0.001)(表3图2)。

图2  比较对照组与病例组组间与亚组间T1-mapping值的箱线图。
Fig. 2  Box plots comparing T1-mapping values between the control group and the case group and between subgroups.
表3  对照组、病例组及其亚组间T1-mapping值与ADC50, 500, 700值
Tab. 3  T1-mapping values and ADC50, 500, 700 values in the control group, case group, and their subgroups

2.4 对照组、病例组及其亚组间关节软骨下骨髓ADC50,500,700值对比

       病例组的ADC50, 500, 700值高于对照组,组间差异具有统计学意义(P<0.001)。亚组分析显示,非活动组与活动组的值均高于对照组,组间差异具有统计学意义(P<0.001);活动组的ADC50, 500, 700值高于非活动组的ADC50, 500, 700值,差异具有统计学意义(P=0.004)(表3图3)。

图3  比较对照组与病例组组间与亚组间ADC50, 500, 700值的箱线图。ADC50, 500, 700:三个b值50、500和700 s/mm2拟合计算出的表观扩散系数。
Fig. 3  Box plots comparing ADC50, 500, 700 values between the control group and the case group and between subgroups. ADC50, 500, 700: The apparent diffusion coefficients calculated from three fitted values of b = 50, 500 and 700 s/mm2.

2.5 T1-mapping、RESOLVE DWI在axSpA炎症活动性评估的效能分析

       ROC曲线分析结果显示,T1-mapping值和ADC50, 500, 700值在鉴别对照组、病例组及其亚组均有一定的效能(均P<0.05)(表4图4)。其中,在鉴别非活动组和活动组中(图5图6),T1-mapping值的AUC为0.808,其敏感度和特异度分别为75.00%和79.41%。ADC50, 500, 700值的AUC为0.693,其敏感度和特异度分别为75.00%和55.88%。DeLong检验显示,非活动组和活动组中,T1-mapping值AUC与ADC50, 500, 700值AUC的差异存在统计学意义(Z=2.039,P=0.042),余各组间、亚组间T1-mapping值AUC与ADC50, 500, 700值AUC的差异不具有统计学意义。

图4  T1-mapping值和ADC50, 500, 700值在不同组间的ROC曲线。4A:对照组和病例组ROC曲线;4B:对照组和非活动组ROC曲线;4C:对照组和活动组ROC曲线;4D:非活动组和活动组ROC曲线。ADC50, 500, 700:三个b值50、500和700 s/mm2拟合计算出的表观扩散系数;ROC:受试者工作特征。
Fig. 4  ROC curves for T1-mapping values and ADC50, 500, 700 values across different groups. 4A shows the ROC curves for the control group and case group; 4B shows the ROC curves for the control group and inactive group; 4C shows the ROC curves for the control group and active group; 4D shows the ROC curves for the inactive group and active group. ADC50, 500, 700: The apparent diffusion coefficients calculated from three fitted values of b = 50, 500, and 700 s/mm2; ROC: receiver operating characteristic.
图5  非活动组骶髂关节MRI 表现。女,17 岁,HLA-B27:+,ASDAS:0.6,属于非活动组。5A:PDWI-FS 冠状位,双侧骶髂关节未见明确活动性炎性骨髓水肿征象。5B~5C:病灶感兴趣区ADC50, 500, 700 值为909.7×10−3 mm2/s;T1-mapping 值为590.7 ms。HLA-B27:人类白细胞抗原B27;ASDAS:强直性脊柱炎疾病活动度评分;PDWI-FS:质子密度加权脂肪抑制; ADC50, 500, 700:三个b值50、500和700 s/mm2拟合计算出的表观扩散系数。
Fig. 5  MRI findings of the sacroiliac joint in the inactive group. Female, 17 years old, HLA-B27: positive, ASDAS: 0.6, classified as inactive group. 5A: PDWI-FS coronal view; no definitive signs of active inflammatory bone marrow oedema are observed in the bilateral sacroiliac joints. 5B to 5C: ADC 50, 500, 700 values at regions of interest are 909.7 × 10-3 mm2/s; T1-mapping value is 590.7 ms. HLA-B27: human leukocyte antigen B27; ASDAS: Ankylosing Spondylitis Disease Activity Score; PDWI-FS: proton density weighted imaging with fat suppression; ADC50, 500, 700: The apparent diffusion coefficients calculated from three fitted values of b = 50, 500 and 700 s/mm2.
图6  活动组骶髂关节MRI 表现。男,18 岁,HLA-B27:+ ,ASDAS:4.0,属于活动组。6A:PDWI-FS 冠状位,左侧骶髂关节关节面下骨质边界模糊的片状高信号,相应关节面欠光整。6B~6C:病灶感兴趣区ADC50, 500, 700值为1 334.2×10−3 mm2/s;T1-mapping 值为1 875.5 ms。HLA-B27:人类白细胞抗原B27;ASDAS:强直性脊柱炎疾病活动度评分;PDWI-FS:质子密度加权脂肪抑制;ADC50, 500, 700:三个b值50、500和700 s/mm2拟合计算出的表观扩散系数。
Fig. 6  MRI findings of the sacroiliac joint in the active group. Male, 18 years old, HLA-B27: positive, ASDAS: 4.0, classified as active group. 6A: PDWI-FS coronal view. A patchy, high-signal area with blurred margins is observed beneath the articular surface of the left sacroiliac joint, with corresponding articular surface irregularity. 6B to 6C: The apparent diffusion coefficients calculated from three fitted values of b = 50, 500 and 700 s/mm2 (ADC50, 500, 700) values at regions of interest are mm2/s: 1 334.2 × 10-3 mm2/s; T1-mapping value is 1 875.5 ms. HLA-B27: human leukocyte antigen B27; ASDAS: Ankylosing Spondylitis Disease Activity Score; PDWI-FS: proton density weighted imaging with fat suppression; ADC50, 500, 700: The apparent diffusion coefficients calculated from three fitted values of b = 50, 500 and 700 s/mm2.
表4  T1-mapping值和ADC50, 500, 700值鉴别不同组别的诊断效能
Tab. 4  T1-mapping values and ADC50, 500, 700 values for distinguishing diagnostic efficacy across different groups

3 讨论

       本研究采用T1-mapping与RESOLVE DWI技术,对axSpA病例组及其亚组、对照组的骶髂关节软骨下骨髓定量评估,并进行了对比。结果显示,axSpA病例组及其亚组(非活动期与活动期)骶髂关节软骨下骨髓的T1-mapping值与ADC50, 500, 700值均显著高于对照组,且活动组的这两项参数也显著高于非活动组。此外,在区分非活动组与活动组时,T1-mapping的诊断效能优于 ADC50, 500, 700。T1-mapping与RESOLVE DWI技术能够较好地评估axSpA骶髂关节炎症活动性水平,且在区分axSpA患者非活动组与活动组评估中,T1-mapping技术效能更优。这一结果提示T1-mapping可能更适合作为活动性分层和随访监测的优先选择,有助于减少主观差异,提高复查前后对比的稳定性;而RESOLVE DWI也可作为补充序列,为炎症信息的获取提供额外依据。

3.1 axSpA活动性骶髂关节炎常见评价方法以及局限性

       本研究结果表明,T1-mapping与RESOLVE DWI定量参数均可用于评估axSpA患者骶髂关节炎症活动性,在对照组与病例组、对照组与非活动组、对照组与活动组的鉴别中均显示出较好的诊断效能。2009年,ASAS提出的ASDAS评分[13]作为临床复合评分指标,虽可反映整体疾病活动状态,但其结果并不完全等同于骶髂关节局部炎症负荷。其提及的CRP和ESR作为全身性炎症指标,特异性有限,容易受到其他系统性炎症因素的干扰,从而导致假阳性结果[24]。同时,在骶髂关节MRI评估中,短时反转恢复序列(short tau inversion recovery, STIR)序列被公认为检测骶髂关节炎症活动性的核心工具[25, 26]。然而,STIR序列本质属于形态学定性序列,信号改变滞后于病理进程,且无法对炎症负荷进行精确分级[27]。为降低对主观经验的依赖,临床实践正逐步从定性描述转向精准量化。这种以客观数据为核心的评估方式,使axSpA的疾病管理趋于科学化与精准化。因此寻找一种检测骶髂关节炎症病灶敏感度更高、更客观、可量化的方法具有至关重要的意义。

3.2 T1值与ADC值在评估骶髂关节炎症中的价值

       本研究采用T1-mapping与RESOLVE DWI技术,对axSpA病例组及其亚组、对照组的骶髂关节软骨下骨髓定量评估,并进行了对比。结果显示,axSpA病例组及其亚组(非活动期与活动期)骶髂关节软骨下骨髓的T1-mapping值与ADC50, 500, 700值均显著高于健康对照组,且活动组的这两项参数也显著高于非活动组。这表明,骶髂关节的T1-mapping值与ADC50, 500, 700值均可以反映骶髂关节炎症状态,参数值越高,炎症越活跃。T1-mapping技术凭借其信号稳定、受组织微观环境干扰小的直接测量优势,在骶髂关节炎症活动性评估中优于T2-mapping以及T2*-mapping[28]。既往研究表明,T1-mapping值能灵敏地反映炎症引发的水肿程度,为早期诊断提供可靠的影像学生物标志物。这一价值已获既往研究佐证,DIEKHOFF等[20]的研究证实其能精准评估成分均一的骶髂关节病灶;也有研究表明联合T1-mapping参数模型可进一步提升对炎症活动水平评估的准确性[29]。RESOLVE DWI序列具有在高空间分辨率上显著减轻的变形伪影的优势,从而能清晰呈现关节周围骨髓及软组织的微观水分子扩散信息,通过量化ADC,该技术为评估水分子扩散受限程度提供了客观依据。既往研究充分肯定了DWI序列在axSpA评估中的价值。其中,WANG等[30]的研究指出其诊断效能优于T2-mapping;林敏贵等[31]进一步明确,RESOLVE DWI所获ADC值可作为SpA骶髂关节活动性病变的定量评估指标;另有研究表明,多b值拟合RESOLVE DWI在评估疾病活动度方面独具优势[21]。在技术上,该序列通过有效抑制磁敏感伪影并提升空间分辨率,显著增强了ADC图的准确性与稳定性[32]。研究表明,ADC值能够灵敏地捕捉炎性区域水分子扩散受限的特征,从而直观反映活动性炎症范围,为临床精准分期与疗效评估提供关键依据。同时,ROC曲线分析表明,T1-mapping与RESOLVE DWI在鉴别骶髂关节活动性炎症时均展现出较好的诊断性能,印证了二者兼具高度的敏感性与特异性,可作为可靠的影像学生物标志物应用于临床鉴别诊断。

3.3 T1-mapping鉴别骶髂关节活动期与非活动期的效能优于RESOLVE DWI

       在区分骶髂关节炎活动期与非活动期方面,T1-mapping技术展现出优于RESOLVE序列的判别能力,其优势根源在于T1-mapping较之RESOLVE DWI所受到的干扰更少。axSpA的疾病进程并非线性,而是包含性质不同的病理阶段,在活动期时,核心病理是急性炎症反应,表现为显著的骨髓水肿、血管增生和炎性细胞浸润[33]。这一变化同时导致:水分子扩散严重受限,导致RESOLVE DWI信号显著增高;组织内自由水比例大幅增加,改变了其固有的弛豫环境,导致T1-mapping值显著延长。在此阶段,两种序列均能有效检测到异常。然而非活动期时,axSpA核心病理从急性炎症损伤转变为结构性损伤,包括早期的纤维化和脂肪浸润,这些变化对两种序列的影响产生了关键分歧。对RESOLVE DWI而言,纤维化虽然能限制水扩散,但其效果远不如急性水肿显著;而脂肪浸润则可能因为脂肪分子本身的流动性而导致RESOLVE DWI信号变化不明确。因此,RESOLVE DWI在区分“结构性损害的非活动期”与“剧烈水肿的活动期”时,其信号对比度和特异性下降,导致鉴别能力稍弱于T1-mapping。

       相比之下,纤维化组织中密集的胶原纤维网络会显著加速质子弛豫,导致T1-mapping值缩短;而脂肪浸润则因脂肪特有的短T1特性,同样会引起T1-mapping值的特征性变化。因此,T1-mapping能够精准捕捉到从“水肿浸润”到“纤维/脂肪重塑”这一组织成分的“质变”。既往研究也证实,与T2*-mapping及T2-mapping映射相比,T1-mapping在定量评估中可作为首选方法[28]。此外,T1-mapping不仅对蛋白多糖等基质成分的改变反应灵敏,还能够表征水与细胞外基质在慢运动频率上的交互作用。由于T1-mapping值具有较高的组织特异性,并不受胶原纤维走向的干扰,该序列已被广泛应用关节软骨的生化成像研究[34, 35]。同时,本研究发现在区分对照组与非活动期患者时,RESOLVE DWI的AUC值略高于T1-mapping的AUC值,这可能是由于非活动期病变中可能存在的轻微的组织学改变,如少量残留的水肿,对水分子扩散的影响可能先于对整体T1弛豫环境的改变,使得高分辨率的DWI序列在此细微的鉴别中略显敏感。然而,无统计学意义的结果表明,这种差异可能并不稳定,也恰恰说明在宏观层面,非活动期axSpA的组织材质已通过修复过程接近正常,而T1-mapping准确地反映了这一趋势。这进一步印证了T1-mapping在评估结构性损伤方面的价值,并提示未来结合DWI与T1-mapping的多参数模型,或许能实现对axSpA亚临床状态的更精准探测。

3.4 局限性及展望

       本研究也存在一定的局限性。(1)由于骶髂关节炎的病因多样、病理机制复杂,本次研究重点关注骨髓水肿在T1-mapping和RESOLVE DWI上的的诊断性能,未做脂质沉积、骨质增生硬化等其他改变的定量分析;(2)样本量有限且来自单一中心,可能导致统计效力不足,后续需通过多中心、大样本研究加以验证;(3)本研究采用1.5 T MRI扫描,使用3.0 T MRI设备可能进一步提升T1-mapping与RESOLVE DWI的分辨率,未来研究将验证不同磁场强度下的诊断效能;(4)目前尚未建立基于影像学的定量指标用于骶髂关节炎治疗反应评估,这将作为我们未来的重点研究方向。

4 结论

       T1-mapping与RESOLVE DWI均能够定量评估axSpA骶髂关节炎症活动性,其中T1-mapping在区分axSpA患者非活动组与活动组方面的诊断效能更优,可为axSpA的诊断及活动性评估提供客观的定量指标。

[1]
DOUGADOS M, BAETEN D. Spondyloarthritis[J]. Lancet, 2011, 377(9783): 2127-2137. DOI: 10.1016/S0140-6736(11)60071-8.
[2]
SIEPER J, PODDUBNYY D. Axial spondyloarthritis[J]. Lancet, 2017, 390(10089): 73-84. DOI: 10.1016/S0140-6736(16)31591-4.
[3]
SARIYILDIZ E, DURUÖZ M T, GEZER H H, et al. Clinical characteristics of peripheral joint disease in axial and peripheral spondyloarthritis: findings from a multicentre cross-sectional study[J/OL]. Rheumatol Int, 2025, 45(12): 271 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/41214168/. DOI: 10.1007/s00296-025-06021-z.
[4]
TAHIR K, AKASBI N, MEZOUAR I EL, et al. The burden of extra-articular manifestations in axial spondyloarthritis: a Moroccan single-centre study[J]. Musculoskeletal Care, 2025, 23(2): e70087. DOI: 10.1002/msc.70087.
[5]
FATTORINI F, GENTILESCHI S, CIGOLINI C, et al. Axial spondyloarthritis: one year in review 2023[J]. Clin Exp Rheumatol, 2023, 41(11): 2142-2150. DOI: 10.55563/clinexprheumatol/9fhz98.
[6]
STOLWIJK C, VAN ONNA M, BOONEN A, et al. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis[J]. Arthritis Care Res, 2016, 68(9): 1320-1331. DOI: 10.1002/acr.22831.
[7]
BITTAR M, DEODHAR A. Axial spondyloarthritis: a review[J]. JAMA, 2025, 333(5): 408-420. DOI: 10.1001/jama.2024.20917.
[8]
REVEILLE J D, EDER L, ZIADE N, et al. Global epidemiology of spondyloarthritis[J]. Nat Rev Rheumatol, 2025, 21(10): 580-598. DOI: 10.1038/s41584-025-01286-x.
[9]
RAMIRO S, NIKIPHOROU E, SEPRIANO A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update[J]. Ann Rheum Dis, 2023, 82(1): 19-34. DOI: 10.1136/ard-2022-223296.
[10]
NAVARRO-COMPÁN V, SEPRIANO A, CAPELUSNIK D, et al. Axial spondyloarthritis[J]. Lancet, 2025, 405(10473): 159-172. DOI: 10.1016/S0140-6736(24)02263-3.
[11]
ALONSO S, BRAÑA I, LOREDO M, et al. Performance of disease activity indices used in axial spondyloarthritis in real-world clinical settings[J]. J Rheumatol, 2025, 52(5): 444-449. DOI: 10.3899/jrheum.2024-0916.
[12]
VAN DER HEIJDE D, RAMIRO S, LANDEWÉ R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis[J]. Ann Rheum Dis, 2017, 76(6): 978-991. DOI: 10.1136/annrheumdis-2016-210770.
[13]
LUKAS C, LANDEWÉ R, SIEPER J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis[J]. Ann Rheum Dis, 2009, 68(1): 18-24. DOI: 10.1136/ard.2008.094870.
[14]
MANDL P, NAVARRO-COMPÁN V, TERSLEV L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice[J]. Ann Rheum Dis, 2015, 74(7): 1327-1339. DOI: 10.1136/annrheumdis-2014-206971.
[15]
WEBER U, JURIK A G, LAMBERT R G W, et al. Imaging in axial spondyloarthritis: what is relevant for diagnosis in daily practice [J/OL]. Curr Rheumatol Rep, 2021, 23(8): 66 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/34218356/. DOI: 10.1007/s11926-021-01030-w.
[16]
LAVIELLE A, PINAUD N, ZHANG B, et al. Quantitative brain T1 maps derived from T1-weighted MRI acquisitions: a proof-of-concept study[J/OL]. Eur Radiol Exp, 2024, 8(1): 109 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/39377962/. DOI: 10.1186/s41747-024-00517-2.
[17]
MITTAL S, PRADHAN G, SINGH S, et al. T1 and T2 mapping of articular cartilage and menisci in early osteoarthritis of the knee using 3-Tesla magnetic resonance imaging[J/OL]. Pol J Radiol, 2019, 84: e549-e564 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/32082454/. DOI: 10.5114/pjr.2019.91375.
[18]
BOUHSINA N, DECANTE C, HARDEL J B, et al. Comparison of MRI T1, T2, and T2* mapping with histology for assessment of intervertebral disc degeneration in an ovine model[J/OL]. Sci Rep, 2022, 12(1): 5398 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/35354902/. DOI: 10.1038/s41598-022-09348-w.
[19]
ABDULAAL O M, MACMAHON P J, RAINFORD L, et al. Evaluation of image quality of diffusion weighted readout segmentation of long variable echo-trains MR pulse sequence for lumbosacral nerve imaging at 3T[J]. Quant Imaging Med Surg, 2023, 13(1): 196-209. DOI: 10.21037/qims-22-191.
[20]
DIEKHOFF T, DEPPE D, PODDUBNYY D, et al. Characterization of bone marrow lesions in axial spondyloarthritis using quantitative T1 mapping MRI[J]. Skeletal Radiol, 2024, 53(7): 1295-1302. DOI: 10.1007/s00256-024-04583-w.
[21]
CHEN X Y, YANG S S, LIN M G, et al. Multi-b-values-fitting readout-segmentation of long variable echo-trains diffusion-weighted imaging (RESOLVE DWI) in evaluation of disease activity and curative effect of axial spondyloarthritis (axSpA)[J/OL]. Front Immunol, 2023, 14: 1136925 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/37465672/. DOI: 10.3389/fimmu.2023.1136925.
[22]
ZHANG H, HUANG H J, ZHANG Y Y, et al. Diffusion-weighted MRI to assess sacroiliitis: improved image quality and diagnostic performance of readout-segmented echo-planar imaging (EPI) over conventional single-shot EPI[J]. AJR Am J Roentgenol, 2021, 217(2): 450-459. DOI: 10.2214/AJR.20.23953.
[23]
ZEIDLER H, AMOR B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress[J/OL]. Ann Rheum Dis, 2011, 70(1): 1-3 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/21163805/. DOI: 10.1136/ard.2010.135889.
[24]
STEC-MARTYNA E, WOJTCZAK K, NOWAK D, et al. Battle of the biomarkers of systemic inflammation[J/OL]. Biology, 2025, 14(4): 438 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/40282303/. DOI: 10.3390/biology14040438.
[25]
SIEPER J, RUDWALEIT M, BARALIAKOS X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis[J/OL]. Ann Rheum Dis, 2009, 68(Suppl 2): ii1-ii44 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/19433414/. DOI: 10.1136/ard.2008.104018.
[26]
LAMBERT R G, BAKKER P A, VAN DER HEIJDE D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group[J]. Ann Rheum Dis, 2016, 75(11): 1958-1963. DOI: 10.1136/annrheumdis-2015-208642.
[27]
KOYUN M, ARDA K N. Diagnostic value of T2 mapping in sacroiliitis associated with spondyloarthropathy[J/OL]. Diagnostics (Basel), 2025, 15(13): 1634 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/40647633/. DOI: 10.3390/diagnostics15131634.
[28]
LIN M G, CHEN X Y, YU S, et al. Monitoring the efficacy of tumor necrosis factor alpha antagonists in the treatment of Ankylosing spondylarthritis: a pilot study based on MR relaxometry technique[J/OL]. BMC Med Imaging, 2021, 21(1): 117 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/34330227/. DOI: 10.1186/s12880-021-00646-9.
[29]
YANG S S, ZHENG Y H, CHEN X Y, et al. Inflammatory activity evaluation in patients with axial spondyloarthritis using MRI relaxometry and mucosal-associated invariant T cells[J/OL]. Front Immunol, 2024, 15: 1391280 [2025-12-02]. https://pubmed.ncbi.nlm.nih.gov/38840918/. DOI: 10.3389/fimmu.2024.1391280.
[30]
WANG D D, YIN H J, LIU W L, et al. Comparative analysis of the diagnostic values of T2 mapping and diffusion-weighted imaging for sacroiliitis in ankylosing spondylitis[J]. Skeletal Radiol, 2020, 49(10): 1597-1606. DOI: 10.1007/s00256-020-03442-8.
[31]
林敏贵, 陈贤源, 俞顺, 等. RESOLVE弥散加权成像评估中轴型脊柱关节炎骶髂关节活动性病变[J]. 中国医学影像技术, 2021, 37(4): 587-592. DOI: 10.13929/j.issn.1003-3289.2021.04.025.
LIN M G, CHEN X Y, YU S, et al. RESOLVE diffusion weighted imaging in evaluation on sacroiliac joint active lesions caused by axial spondyloarthritis[J]. Chin J Med Imaging Technol, 2021, 37(4): 587-592. DOI: 10.13929/j.issn.1003-3289.2021.04.025.
[32]
MOHANASUNDARAM P, KUMAR J, PRADHAN G S, et al. Role of resolve DWI and DCE MRI in differentiating benign and malignant skull base lesions[J]. Neuroradiology, 2025, 67(9): 2573-2583. DOI: 10.1007/s00234-025-03760-5.
[33]
MAURO D, GANDOLFO S, TIRRI E, et al. The bone marrow side of axial spondyloarthritis[J]. Nat Rev Rheumatol, 2023, 19(8): 519-532. DOI: 10.1038/s41584-023-00986-6.
[34]
于海霞, 沈怡颖, 张晏境, 等. 定量MRI技术在跑步人群膝关节软骨中的应用进展[J]. 国际医学放射学杂志, 2022, 45(5): 588-593. DOI: 10.19300/j.2022.Z19608.
YU H X, SHEN Y Y, ZHANG Y J, et al. Application progress of quantitative MRI technologies in evaluating knee cartilage of runners[J]. Int J Med Radiol, 2022, 45(5): 588-593. DOI: 10.19300/j.2022.Z19608.
[35]
高艺洋, 李相生. 踝关节软骨损伤的功能磁共振成像研究进展[J]. 磁共振成像, 2022, 13(9): 167-170. DOI: 10.12015/issn.1674-8034.2022.09.040.
GAO Y Y, LI X S. The latest research progress of functional MRI in traumatic cartilage injury of ankle joint[J]. Chin J Magn Reson Imaging, 2022, 13(9): 167-170. DOI: 10.12015/issn.1674-8034.2022.09.040.

上一篇 基于BioMatrix系统的呼吸触发与膈肌导航对上腹部T2加权脂肪抑制图像质量及扫描效率的对比研究
下一篇 嗅觉行为学测试与MRI在T2DM认知功能减退早期诊断及干预中的研究进展
  
诚聘英才 | 广告合作 | 免责声明 | 版权声明
联系电话:010-67113815
京ICP备19028836号-2